Our Story
Since our founding in 2011, H3 has been committed to finding and developing novel potential treatments in our quest to treat cancer.
January 2011
H3 Biomedicine founded by Eisai, $200M funding commitment
August 2011
H3 Biomedicine announces start of scientific operations at Kendall Square
February 2015
H3 and Foundation Medicine announce collaboration to discover novel targets
April 2016
IND Acceptance for Phase 1 H3B-8800 novel splicing modulator in advanced myeloid malignancies
April 2016
IND Acceptance for Phase 1 H3B-6527 FGFR4 inhibitor for HCC
June 2017
IND Acceptance for Phase 1 H3B-6545 novel ER antagonist for ER+ mBrCa
December 2018
H3 and Bristol Myers Squibb begin research collaboration to advance novel therapeutics leveraging H3’s RNA splicing platform
May 2019
IND Acceptance for Phase 1 E7766 STING Agonist
July 2019
H3 joined the Cancer Dependency Map (DepMap) Consortium